Lyme disease therapeutic - LondonPharmaAlternative Names: Artemisinin-based Lyme disease therapeutic - LondonPharma; Lyme disease repurposed therapeutic - LondonPharma
Latest Information Update: 17 Dec 2014
At a glance
- Originator LondonPharma
- Class Artemisinins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Lyme disease
Most Recent Events
- 26 Nov 2014 Phase-I clinical trials in Lyme disease in United Kingdom (Sublingual) before November 2014
- 13 Jul 2014 Lyme disease therapeutic - LondonPharma is available for licensing as of 17 Dec 2014.